Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC phase II trial of pertuzumab + trastuzumab with or without metronomic cyclophosphamide in older patients with HER2-positive metastatic breast cancer
NL-OMON41641Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab, trastuzumab, cyclophosphamide and trastuzumab emtansine in breast cancer (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival rate at 6 months. Started Apr 2014; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON41641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41641.